Literature DB >> 6291693

Spectrum of the mu, delta- and kappa-binding sites in homogenates of rat brain.

M G Gillan, H W Kosterlitz.   

Abstract

1 In homogenates of rat brain, the binding characteristics of tritiated opiates and opioid peptides were examined and the relative capacities of mu-, delta- and kappa-binding sites of the opiate receptor determined by saturation analysis.2 In competition experiments, binding of the selective mu-ligand [(3)H]-[D-Ala(2),MePhe(4),Gly-ol(5)]enkephalin at the mu-site was displaced by [D-Ala(2),D-Leu(5)]enkephalin with rather low affinity (K(I) = 12.6 nM) and more readily by the ketazocine-like compounds (-)-ethylketazocine (K(I) = 3.1 nM) and (-)-bremazocine (K(I) = 0.32 nM), which also displaced the binding of [(3)H]-[D-Ala(2),D-Leu(5)]enkephalin from the delta-site. In contrast, the binding to the kappa-site was easily displaced by ethylketazocine (1.0 nM) and bremazocine (0.37 nM) but not by the mu-ligand [D-Ala(2),MePhe(4),Gly-ol(5)]enkephalin (K(I) = 2000-3000 nM) or the delta-ligand [D-Ala(2),D-Leu(5)]enkephalin (K(I) > 20,000 nM).3 The dissociation equilibrium constant (K(D)) and the binding capacity (pmol/g) of the mu-binding site were determined with the selective mu-ligand [(3)H]-[D-Ala(2),MePhe(4),Gly-ol(5)]enkephalin. For the delta-site, [(3)H]-[D-Ala(2),D-Leu(5)]enkephalin was used in the presence of unlabelled [D-Ala(2),MePhe(4),Gly-ol(5)]enkephalin in order to suppress cross-reactivity to the mu-binding site. For the estimation of kappa-binding, [(3)H]-(+/-)-ethylketazocine or [(3)H]-(-)-bremazocine were used in the presence of unlabelled mu- and delta-ligands for the suppression of cross-reactivities to the mu- and delta-binding sites.4 In rat brain the capacity of the mu-binding site was 7.3 pmol/g brain, that of the delta-binding site 6.7 pmol/g brain and that of the kappa-binding site 2.0 pmol/g brain. Thus, the kappa-binding site had the lowest value whereas in the guinea-pig brain the capacity of the mu-binding site was lower than that of the delta- or kappa-binding site.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6291693      PMCID: PMC2044623          DOI: 10.1111/j.1476-5381.1982.tb09319.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  13 in total

1.  3H-ethylketocyclazocine binding: lack of evidence for a separate kappa receptor in rats CNS.

Authors:  J M Hiller; E J Simon
Journal:  Eur J Pharmacol       Date:  1979-12-20       Impact factor: 4.432

2.  Characterization of opioid receptors in nervous tissue.

Authors:  H W Kosterlitz; S J Paterson
Journal:  Proc R Soc Lond B Biol Sci       Date:  1980-10-29

Review 3.  Multiple neurotransmitter receptors.

Authors:  S H Snyder; R R Goodman
Journal:  J Neurochem       Date:  1980-07       Impact factor: 5.372

4.  Bremazocine: a potent, long-acting opiate kappa-agonist.

Authors:  D Römer; H Büscher; R C Hill; R Maurer; T J Petcher; H B Welle; H C Bakel; A M Akkerman
Journal:  Life Sci       Date:  1980-09-15       Impact factor: 5.037

5.  Specific, high affinity [3H]ethylketocyclazocine binding in rat central nervous system: lack of evidence for kappa receptors.

Authors:  J M Hiller; E J Simon
Journal:  J Pharmacol Exp Ther       Date:  1980-09       Impact factor: 4.030

6.  Multiple opiate receptors: [3H]ethylketocyclazocine receptor binding and ketocyclazocine analgesia.

Authors:  G W Pasternak
Journal:  Proc Natl Acad Sci U S A       Date:  1980-06       Impact factor: 11.205

7.  Comparison of the binding characteristics of tritiated opiates and opioid peptides.

Authors:  M G Gillan; H W Kosterlitz; S J Paterson
Journal:  Br J Pharmacol       Date:  1980-11       Impact factor: 8.739

8.  High affinity binding of [3H]ethylketocyclazocine to rat brain homogenate.

Authors:  D W Harris; V H Sethy
Journal:  Eur J Pharmacol       Date:  1980-08-22       Impact factor: 4.432

9.  Analogues of beta-LPH61-64 possessing selective agonist activity at mu-opiate receptors.

Authors:  B K Handa; A C Land; J A Lord; B A Morgan; M J Rance; C F Smith
Journal:  Eur J Pharmacol       Date:  1981-04-09       Impact factor: 4.432

10.  Characterization of the kappa-subtype of the opiate receptor in the guinea-pig brain.

Authors:  H W Kosterlitz; S J Paterson; L E Robson
Journal:  Br J Pharmacol       Date:  1981-08       Impact factor: 8.739

View more
  31 in total

1.  Differential cardiovascular and respiratory responses to central administration of selective opioid agonists in conscious rabbits: correlation with receptor distribution.

Authors:  C N May; M R Dashwood; C J Whitehead; C J Mathias
Journal:  Br J Pharmacol       Date:  1989-11       Impact factor: 8.739

2.  Presynaptic opioid receptors on noradrenergic and serotonergic neurons in the human as compared to the rat neocortex.

Authors:  Benjamin Berger; Anna Katharina Rothmaier; Franziska Wedekind; Josef Zentner; Thomas J Feuerstein; Rolf Jackisch
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

3.  Evidence that the agonist action of dynorphin A(1-8) in the guinea-pig myenteric-plexus may be mediated partly through conversion to [Leu5]enkephalin.

Authors:  D M Dixon; J R Traynor
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

4.  "DAKLI": a multipurpose ligand with high affinity and selectivity for dynorphin (kappa opioid) binding sites.

Authors:  A Goldstein; J J Nestor; A Naidu; S R Newman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

5.  Interactions of isamoltane (CGP 361A), an anxiolytic phenoxypropanolamine derivative, with 5-HT1 receptor subtypes in the rat brain.

Authors:  P C Waldmeier; M Williams; P A Baumann; S Bischoff; M A Sills; R F Neale
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-06       Impact factor: 3.000

6.  Chimeric opioid peptides: tools for identifying opioid receptor types.

Authors:  G X Xie; A Miyajima; T Yokota; K Arai; A Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

7.  Differential sensitivity of models of antinociception in the rat, mouse and guinea-pig to mu- and kappa-opioid receptor agonists.

Authors:  A G Hayes; M J Sheehan; M B Tyers
Journal:  Br J Pharmacol       Date:  1987-08       Impact factor: 8.739

8.  Pharmacological profile of various kappa-agonists at kappa-, mu- and delta-opioid receptors mediating presynaptic inhibition of neurotransmitter release in the rat brain.

Authors:  A H Mulder; D M Burger; G Wardeh; F Hogenboom; A L Frankhuyzen
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

9.  Opioid receptors in midbrain dopaminergic regions of the rat. I. Mu receptor autoradiography.

Authors:  D C German; S G Speciale; K F Manaye; M Sadeq
Journal:  J Neural Transm Gen Sect       Date:  1993

10.  Guanine nucleotide-binding protein-coupled and -uncoupled states of opioid receptors and their relevance to the determination of subtypes.

Authors:  A Richardson; C Demoliou-Mason; E A Barnard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.